Prognostic role of the recepteur d'origine nantais (RON) expression in ovarian cancer patients

Gynecologic Oncology

Volumn 111, Issue 2, 2008, Pages 237-243

  Ferrandina, Gabriella ^a,b   Martinelli, Enrica ^a   Petrillo, Marco ^b   Prisco, Maria Grazia ^a   Zucconi, Adriana ^c   Santaguida, Salvatore ^a   Zannoni, Gianfranco ^b   Scambia, Giovanni ^b   Ferlini, Cristiano ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c IRBM   (Italy)

Author keywords

Ovarian cancer; Prognosis; RON protein

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; PROTEIN RON; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT CANCER; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; SURVIVAL RATE; YOUNG ADULT;

EID: 55649116204     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.07.013     Document Type: Article

References (26)

1. Eisenkop S., Spirtos N.M., Friedman R.L., Lin W.C., Pisani A.L., and Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol. Oncol. 90 (2003) 390-396
2. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D.L., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 (2003) 3194-3200
3. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. Ca Cancer J. Clin. 57 (2007) 43-66
4. Armstrong D. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 7 (2007) 20-28
5. Ronsin C., Muscatelli F., Mattei M.G., and Breathnach R. A novel putative receptor protein tyrosine kinase of the met family. Oncogene 8 (1993) 1195-1202
6. Wang M.H., Yao H.P., and Zhou Y.Q. Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers. Acta Pharmacol. Sin. 27 (2006) 641-650
7. Boccaccio C., and Comoglio P.M. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat. Rev Cancer 6 (2006) 637-645
8. Camp E.R., Liu W., Fan F., Yang A., Somcio R., and Ellis L.M. RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Ann. Surg. Oncol. 12 (2005) 273-281
9. Wang M.H., Lee W., Luo Y.L., Weis M.T., and Yao H.P. Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumorigenic phenotypes in thyroid cancer cells. J. Pathol. 213 (2007) 402-411
10. Zhou Y.Q., He C., Chen Y.Q., Wang D., and Wang M.H. Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential. Oncogene 22 (2003) 186-197
11. Cheng H.L., Liu H.S., Lin Y.J., Chen H.H.W., Hsu P.Y., Chang T.Y., et al. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br. J. Cancer 92 (2005) 1906-1914
12. Maggiora P., Lorenzato A., Fracchioli S., Costa B., Castagnaro M., and Arisio R. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp. Cell Res. 288 (2003) 382-389
13. Lee W.Y., Chen H.H.W., Chow N.H., Su W.C., Lin P.W., and Guo H.R. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin. Cancer Res. 11 (2005) 2222-2224
14. World Health Organization. WHO Handbook for reporting results of Cancer Treatment vol. 48 (1979), WHO, Geneva 16-21 offset publication
15. Ferrandina G., Ludovisi M., De Vincenzo R., Salutari V., Lorusso D., Colangelo M., et al. Docetaxel and oxaliplatin in the second-line treatment of platinum sensitive recurrent ovarian cancer: a phase II study. Ann. Oncol. 18 (2007) 1348-1353
16. Ferrandina G., Ludovisi M., Lorusso D., Pignata S., Breda E., Savarese A., et al., On behalf of MITO (Multicenter Italian Trials in Ovarian cancer) Group. Gemcitabine versus pegylated liposomal doxorubicin in progressive/recurrent ovarian cancer: the multicenter Italian trials in ovarian cancer (MITO-3) randomized phase III study. J Clin Oncol 26 6 (2008) 1-7
17. Kaplan E., and Meyer P. Non parametric estimation from incomplete observations. J. Am. Stat. Assoc. 53 (1958) 457-481
18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50 (1966) 163-170
19. Cox D.R. Regression models and life tables. J. R. Stat. Soc. 34 (1972) 197-220
20. Di Renzo M.F., Olivero M., Katsaros D., Crepaldi T., Gaglia P., Zola P., et al. Overexpression of the Met/HGF receptor in ovarian cancer. Int. J. Cancer 58 (1994) 658-662
21. Corps A.N., Sowter H.M., and Smith S.K. Hepatocyte growth factor stimulates motility,chemotaxis and mitogenesis in ovarian carcinoma cells expressing high levels of c-met. Int. J. Cancer 73 (1997) 151-155
22. Wong A.S., Pelech S.L., Woo M.M., Yim G., Rosen B., Ehlen T., et al. Coexpression of hepatocyte growth factor-Met-an early step in ovarian carcinogenesis. Oncogene 20 (2001) 1318-1328
23. Bellusci S., Moens G., Gaudino G., et al. Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity. Oncogene 9 (1994) 1091-1099
24. Camp E.R., Yang A., Gray M., Fan F., Hamilton S.R., Evans D.B., et al. Tyrosine kinase receptro RON in human pancreatic cancer. Cancer 109 (2007) 1030-1039
25. Bardelli A.S., Basile M.L., Audero E., et al. Concomitant activation of pathways downstream of Grb2 and PI 3 kinase is required for MET-mediated metastasis. Oncogene 18 (1999) 1139-1146
26. O'Toole J.M., Rabenau K.E., Burns K., et al. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res. 66 (2006) 9162-9170